Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
No Longer Available NCT05389514

Intermediate-size IND for Treatment of KRAS G12V-mutant Tumors

Conditions: KRAS G12V Mutant Advanced Epithelial Cancers

Sex: All
Ages: 18 Years – N/A
Sponsor: Providence Health & Services

Summary

This intermediate-size IND will treat participants with incurable, advanced or metastatic cancer, harboring KRAS G12V mutation and appropriate HLA class II match (HLA-DRB1\*07:01).

Eligibility Criteria

Patients with incurable, advanced or metastatic cancer, harboring KRAS G12V mutation, and appropriate HLA class II match (HLA-DRB1\*07:01)

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05389514). StuddyBuddy aggregates publicly available trial information.